Our data provide further evidence for the efficacy of complement inhibition in pneumococcal meningitis, supporting the need for a phase II clinical trial to evaluate the effect of combined adjunctive dexamethasone plus C5-antibody treatment in patients with pneumococcal meningitis. Here, C5 is linked to pneumococcal meningitis.